新闻 打印 2022Mayo Clinic research shows bebtelovimab to be a reliable option for treating COVID-19 in era of BA.2, other subvariants Aug. 15, 2022, 02:09 p.m. CDTPatients treated with monoclonal antibodies during COVID-19 delta surge had low rates of severe disease, Mayo Clinic study finds June 27, 2022, 03:00 p.m. CDTStudy finds few COVID-19 patients get rebound symptoms after Paxlovid treatment June 14, 2022, 10:06 a.m. CDT PST-20223091 主页 新闻